Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
US Army
Julphar
US Department of Justice
Express Scripts
Deloitte
Dow
Queensland Health

Generated: July 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,335,031

« Back to Dashboard

Which drugs does patent 6,335,031 protect, and when does it expire?

Patent 6,335,031 protects EXELON and is included in one NDA.

This patent has thirty-four patent family members in twenty-seven countries.
Summary for Patent: 6,335,031
Title: TTS containing an antioxidant
Abstract:Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Inventor(s): Asmussen; Bodo (Bendorf-Sayn, DE), Horstmann; Michael (Neuwied, DE), Kopke; Kai (Triengen, CH), Tiemessen; Henricus L. G. M. (Weil-Haltingen, DE), Dinh; Steven Minh (Briarcliff Manor, NY), Gargiulo; Paul M. (New York, NY)
Assignee: Novartis AG (Basel, CH) LTS Lohmann Therapie-Systeme GmbH Co. KG (Neuwied, DE)
Application Number:09/291,498
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,335,031
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Drugs Protected by US Patent 6,335,031

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-001 Jul 6, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-005 Aug 31, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,335,031

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany9800526Jan 12, 1998

Non-Orange Book US Patents Family Members for Patent 6,335,031

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,316,023 TTS containing an antioxidant ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Moodys
Cerilliant
Harvard Business School
Julphar
AstraZeneca
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.